LAGRAXA Trademark

Trademark Overview

On Thursday, December 1, 2016, a trademark application was filed for LAGRAXA with the United States Patent and Trademark Office. The USPTO has given the LAGRAXA trademark a serial number of 87254077. The federal status of this trademark filing is REGISTERED as of Tuesday, June 30, 2020. This trademark is owned by Apotex Technologies Inc.. The LAGRAXA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for hematopoietic growth factors; pharmaceutical preparations, namely, recombinant-human granulocyte-CSF for use in stimulating white blood cell production
lagraxa

General Information

Serial Number87254077
Word MarkLAGRAXA
Filing DateThursday, December 1, 2016
Status700 - REGISTERED
Status DateTuesday, June 30, 2020
Registration Number6088028
Registration DateTuesday, June 30, 2020
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 11, 2020

Trademark Statements

Goods and ServicesPharmaceutical preparations for hematopoietic growth factors; pharmaceutical preparations, namely, recombinant-human granulocyte-CSF for use in stimulating white blood cell production

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, December 7, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAPOTEX INC.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressTORONTO M9L1T9
CA
Party NameAPOTEX INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressTORONTO, ONTARIO M9L1T9
CA
Party NameAPOTEX INC.
Party Type11 - New Owner Before Publication
Legal Entity Type03 - Corporation
AddressTORONTO, ONTARIO M9L1T9
CA
Party NameApotex Technologies Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressToronto, Ontario M9L1T9
CA

Trademark Events

Event DateEvent Description
Wednesday, July 19, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, July 19, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, July 19, 2023TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Wednesday, July 19, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, July 19, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, July 19, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, July 19, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, June 30, 2020REGISTERED-PRINCIPAL REGISTER
Tuesday, May 26, 20201(B) BASIS DELETED; PROCEED TO REGISTRATION
Monday, April 27, 2020NOTICE OF ALLOWANCE CANCELLED
Tuesday, May 26, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, April 27, 2020TEAS DELETE 1(B) BASIS RECEIVED
Sunday, April 26, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sunday, April 26, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sunday, April 26, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, April 7, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 11, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 11, 2020PUBLISHED FOR OPPOSITION
Wednesday, January 22, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sunday, January 5, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, January 4, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, January 4, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, December 31, 2019TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Saturday, November 23, 2019NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Saturday, November 23, 2019INQUIRY TO SUSPENSION E-MAILED
Saturday, November 23, 2019SUSPENSION INQUIRY WRITTEN
Monday, November 18, 2019SUSPENSION CHECKED ¿ TO ATTORNEY FOR ACTION
Wednesday, July 3, 2019AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Thursday, May 16, 2019NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, May 16, 2019LETTER OF SUSPENSION E-MAILED
Thursday, May 16, 2019SUSPENSION LETTER WRITTEN
Thursday, May 2, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, May 2, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, April 29, 2019TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Tuesday, November 6, 2018NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Tuesday, November 6, 2018INQUIRY TO SUSPENSION E-MAILED
Tuesday, November 6, 2018SUSPENSION INQUIRY WRITTEN
Thursday, May 3, 2018NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, May 3, 2018LETTER OF SUSPENSION E-MAILED
Thursday, May 3, 2018SUSPENSION LETTER WRITTEN
Wednesday, April 11, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, April 11, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, April 9, 2018TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Monday, November 6, 2017NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Monday, November 6, 2017INQUIRY TO SUSPENSION E-MAILED
Monday, November 6, 2017SUSPENSION INQUIRY WRITTEN
Friday, October 20, 2017SUSPENSION CHECKED ¿ TO ATTORNEY FOR ACTION
Thursday, October 19, 2017ASSIGNED TO LIE
Friday, April 7, 2017NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, April 7, 2017LETTER OF SUSPENSION E-MAILED
Friday, April 7, 2017SUSPENSION LETTER WRITTEN
Monday, April 3, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, April 3, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, April 3, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, February 28, 2017NOTIFICATION OF PRIORITY ACTION E-MAILED
Tuesday, February 28, 2017PRIORITY ACTION E-MAILED
Tuesday, February 28, 2017PRIORITY ACTION WRITTEN
Thursday, February 23, 2017ASSIGNED TO EXAMINER
Wednesday, December 7, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, December 5, 2016NEW APPLICATION ENTERED

Related Keywords

lagraxa pharmaceutical preparations white stimulating cell production granulocyte blood recombinant hematopoietic